NO20025355L - Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII - Google Patents

Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII

Info

Publication number
NO20025355L
NO20025355L NO20025355A NO20025355A NO20025355L NO 20025355 L NO20025355 L NO 20025355L NO 20025355 A NO20025355 A NO 20025355A NO 20025355 A NO20025355 A NO 20025355A NO 20025355 L NO20025355 L NO 20025355L
Authority
NO
Norway
Prior art keywords
factor
pharmaceutical composition
xiii
viia
factor viia
Prior art date
Application number
NO20025355A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025355D0 (no
Inventor
Lars Christian Petersen
Ulla Hedner
Rasmus Roejkjaer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20025355D0 publication Critical patent/NO20025355D0/no
Publication of NO20025355L publication Critical patent/NO20025355L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20025355A 2000-05-10 2002-11-08 Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII NO20025355L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000778 2000-05-10
DKPA200000771 2000-05-10
DKPA200000871 2000-06-06
PCT/DK2001/000322 WO2001085198A1 (fr) 2000-05-10 2001-05-10 Composition pharmaceutique comprenant un facteur viia et un facteur xiii

Publications (2)

Publication Number Publication Date
NO20025355D0 NO20025355D0 (no) 2002-11-08
NO20025355L true NO20025355L (no) 2003-01-09

Family

ID=27222387

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025355A NO20025355L (no) 2000-05-10 2002-11-08 Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII

Country Status (17)

Country Link
US (3) US20030092627A1 (fr)
EP (3) EP1282438B1 (fr)
JP (2) JP2003532684A (fr)
CN (1) CN1304049C (fr)
AT (2) ATE300953T1 (fr)
AU (3) AU5822801A (fr)
BR (1) BR0110659A (fr)
CA (1) CA2406583A1 (fr)
CZ (1) CZ20023667A3 (fr)
DE (2) DE60115422T2 (fr)
DK (1) DK1282438T3 (fr)
ES (2) ES2247106T3 (fr)
HU (1) HUP0301868A3 (fr)
IL (1) IL152554A0 (fr)
NO (1) NO20025355L (fr)
PL (1) PL365042A1 (fr)
WO (2) WO2001085199A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227347B1 (en) * 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1319067A2 (fr) * 2000-09-13 2003-06-18 Novo Nordisk A/S Variants du facteur vii de coagulation humaine
CN101486761A (zh) 2000-09-13 2009-07-22 诺沃挪第克健康护理股份公司 人凝血因子vii变体
CA2427535A1 (fr) * 2000-11-03 2002-05-10 Zymogenetics, Inc. Utilisation du facteur xiii de coagulation sanguine dans le traitement de l'hemophilie a
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
DE60129599T2 (de) * 2000-11-10 2008-04-17 Zymogenetics, Inc., Seattle Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b
EP1359935A1 (fr) * 2001-02-05 2003-11-12 Novo Nordisk Health Care AG Utilisation combinee de polypeptides de facteur vii et de polypeptides de facteur ix
WO2002067980A1 (fr) * 2001-02-21 2002-09-06 Zymogenetics, Inc. Procede de traitement de la maladie de von willebrand
JP2005527471A (ja) * 2001-09-10 2005-09-15 ザイモジェネティクス，インコーポレイティド クマリン−誘発された出血を処理するための方法
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
EP1446148A1 (fr) * 2001-11-09 2004-08-18 Novo Nordisk A/S Composition pharmaceutique comprenant un poylpeptide de facteur vii et un acide epsilon-aminocapronique
WO2003039581A1 (fr) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Composition pharmaceutique comprenant des polypeptides du facteur vii et de l'acide tranexamique
CN101675991A (zh) * 2001-12-21 2010-03-24 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EA008038B1 (ru) 2003-01-08 2007-02-27 Чирон Корпорейшн Стабилизированные водные композиции, содержащие ингибитор пути метаболизма, тканевого фактора (tfpi) или вариант ингибитора пути метаболизма тканевого фактора
ATE547114T1 (de) 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
WO2005107795A1 (fr) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Utilisation du facteur viia dans le traitement de traumas par brulures
WO2005115442A1 (fr) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Utilisation du facteur xiii de coagulation dans le traitement de saignements post-operatoires
WO2006021584A2 (fr) * 2004-08-27 2006-03-02 Novo Nordisk Health Care Ag Purification de polypeptides du facteur xiii a partir de matiere vivante
KR101241434B1 (ko) * 2004-09-10 2013-03-12 파마오리진 에이피에스 국소 기관, 기관지 또는 폐포의 출혈 또는 객혈의 치료방법
AU2005308830B2 (en) 2004-11-23 2012-01-19 Zymogenetics, Inc. Purification of recombinant human factor XIII
EP1855712A2 (fr) * 2005-02-28 2007-11-21 Novo Nordisk Health Care AG Variants du facteur xiii a proprietes ameliorees
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
US8461115B2 (en) 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
JP5122562B2 (ja) * 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
PL2147096T3 (pl) * 2007-04-13 2015-08-31 Catalyst Biosciences Inc Zmodyfikowane polipeptydy czynnika VII i ich zastosowania
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
PL2268267T3 (pl) 2008-04-21 2017-12-29 Novo Nordisk Health Care Ag Kompozycja sucha transglutaminazy
EP2149603A1 (fr) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
BR122021014783B1 (pt) * 2008-12-19 2023-03-14 Baxalta GmbH Peptídeo que se liga a tfpi, uso do peptídeo, composição farmacêutica e método para purificação de tfpi
CN103025345B (zh) * 2010-03-19 2016-01-20 巴克斯特国际公司 Tfpi抑制剂及使用方法
EP2600891B1 (fr) 2010-08-05 2018-01-17 Council of Scientific & Industrial Research Protéines de fusion recombinants possédant des propriétés thrombolytiques et anticoagulantes
AU2013235741C1 (en) 2012-03-21 2017-12-21 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
EP2881463A1 (fr) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variants du facteur IX présentant une activité de coagulation en l'absence de leur cofacteur et/ou à une activité de coagulation F.IX accrue et leur utilisation pour traiter des troubles de saignement
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN112424593A (zh) 2018-07-25 2021-02-26 索尼公司 凝血系统分析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
EP3833381B1 (fr) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Polypeptides de facteur vii modifiés pour une administration sous-cutanée

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
AU593042B2 (en) * 1985-11-26 1990-02-01 Novo Nordisk Health Care Ag Compositions and methods for the treatment of bleeding disorders
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
CZ83194A3 (en) * 1991-10-11 1994-11-16 Novo Nordisk As Haemostatic preparation for inducing blood precipitation on a bleeding wound
JPH07502734A (ja) * 1991-12-31 1995-03-23 ザイモジェネティクス，インコーポレイティド 血液損失を減少する方法および組成物
EP0651655A4 (fr) * 1992-07-24 1996-05-29 Oklahoma Med Res Found Reduction d'hemorragie microvasculaire en cours de chirurgie par blocage d'activation de proteine c.
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
JP2002514948A (ja) * 1996-02-20 2002-05-21 コーヒージョン・コーポレーション 組織シーラント組成物とその使用方法
WO1998058661A1 (fr) * 1997-06-23 1998-12-30 Novo Nordisk A/S UTILISATION DU FVIIa POUR TRAITER DES HEMORRAGIES CHEZ DES PATIENTS PRESENTANT UNE CASCADE DE COAGULATION SANGUINE NORMALE ET UNE FONCTION PLAQUETTAIRE NORMALE
EP1041999A1 (fr) * 1997-12-23 2000-10-11 Nuvas LLC Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral
JP2002514433A (ja) * 1998-05-14 2002-05-21 バッテル メモリアル インスティテュート トランスジェニック植物由来ヒト凝血因子
EP1148427A1 (fr) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Procédé et système pour la création d'un bouton de signet dans un navigateur Web representant une partie du fichier correspondant choisie par l'utilisateur
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
EP1359935A1 (fr) * 2001-02-05 2003-11-12 Novo Nordisk Health Care AG Utilisation combinee de polypeptides de facteur vii et de polypeptides de facteur ix
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
EP1446150A1 (fr) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Composition pharmaceutique contenant des polypeptides associes au facteur vii et des inhibiteurs de la proteine c
EP1446148A1 (fr) * 2001-11-09 2004-08-18 Novo Nordisk A/S Composition pharmaceutique comprenant un poylpeptide de facteur vii et un acide epsilon-aminocapronique
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides

Also Published As

Publication number Publication date
ATE300953T1 (de) 2005-08-15
ES2247106T3 (es) 2006-03-01
EP1593389A1 (fr) 2005-11-09
NO20025355D0 (no) 2002-11-08
US20070280920A1 (en) 2007-12-06
PL365042A1 (en) 2004-12-27
EP1282438B1 (fr) 2005-08-03
CN1429117A (zh) 2003-07-09
IL152554A0 (en) 2003-05-29
ATE311198T1 (de) 2005-12-15
DE60112429T2 (de) 2006-06-01
DK1282438T3 (da) 2005-11-14
JP2003532684A (ja) 2003-11-05
CA2406583A1 (fr) 2001-11-15
CN1304049C (zh) 2007-03-14
HUP0301868A2 (hu) 2003-08-28
EP1282439A1 (fr) 2003-02-12
AU2001258228B2 (en) 2006-01-12
DE60115422T2 (de) 2006-08-17
EP1282438A1 (fr) 2003-02-12
JP2004505016A (ja) 2004-02-19
DE60112429D1 (de) 2005-09-08
CZ20023667A3 (cs) 2003-04-16
WO2001085198A1 (fr) 2001-11-15
US20060199766A1 (en) 2006-09-07
WO2001085199A1 (fr) 2001-11-15
BR0110659A (pt) 2003-02-11
ES2254414T3 (es) 2006-06-16
DE60115422D1 (de) 2006-01-05
EP1282439B1 (fr) 2005-11-30
AU2001258230A1 (en) 2001-11-20
HUP0301868A3 (en) 2006-11-28
AU5822801A (en) 2001-11-20
US20030092627A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
NO20025355D0 (no) Farmasöytisk preparat som omfatter en faktor VIIa og en faktor XIII
SE0102315D0 (sv) Compounds
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20033100D0 (no) Uorganiske matrikssammensetninger og kompositter som inneholder matrikssammensetningen
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
ATE331500T1 (de) Synergistische orale zusammensetzung gegen zahnbelag und gingivitis
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
IS6741A (is) Samsetning til að gera tennur hvítar og aðferð sem notar díkarboxýlsýru sem hvítunarmiðil
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
DE60204584D1 (de) Zusammensetzungen enthaltend eine niedrige konzentration an peroxide zur behandlung von vaginitis
ITTO20010804A0 (it) Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
NO20014946L (no) Strukturerte multiformåls-pakkinger og deres anvendelse
DE60225446D1 (de) Flammgeschützte zusammensetzung und artikel
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias
DK1423429T3 (da) Antistoffer mod caspase-8 og deres fremstilling og anvendelse
DE50310272D1 (de) Verdicktes kationisches kosmetisches Mittel Inulin enthaltend
FI990736A (fi) Suoja- tai säilöntäainekoostumus, sen valmistusmenetelmä sekä sen käyttö
MXPA03000780A (es) Derivados de acetamida y uso como inhibidores de los factores de coagulacion xa y viia.
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
IT1318398B1 (it) Procedimento per ossidare in assenza di ossigeno molecolare adattimateriali solidi.
SE0002001D0 (sv) Surface treatment composition

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application